Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genmab ( (GMAB) ) has shared an announcement.
On March 10, 2025, Genmab A/S announced that Johnson & Johnson decided not to exercise its option to license HexaBody-CD38 for development and commercialization. Despite promising clinical data, Genmab will not continue its development due to market landscape evaluations and portfolio prioritization. The decision does not affect Genmab’s 2025 financial guidance, and the company remains focused on its existing pipeline, including EPKINLY and other late-stage assets.
More about Genmab
Genmab A/S is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.
YTD Price Performance: 14.95%
Average Trading Volume: 1,328,004
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.32B
For an in-depth examination of GMAB stock, go to TipRanks’ Stock Analysis page.